Antag Therapeutics Closes Euros80 Million Series A Financing
December 14, 2024
December 14, 2024
BOSTON, Massachusetts, Dec. 14 -- Goodwin, a law firm, issued the following news release:
A cross-border Goodwin Life Sciences team advised a syndicate of investors including Versant Ventures, Dawn Biopharma (a platform controlled by KKR), SR One and Pictet Alternative Advisors on their investment into the Euros80 Million Series A Financing of Antag Therapeutics. Other investors in the round included Novo Holdings, Longview Ventures (an affiliate of Broadview Ventures), and Export a . . .
A cross-border Goodwin Life Sciences team advised a syndicate of investors including Versant Ventures, Dawn Biopharma (a platform controlled by KKR), SR One and Pictet Alternative Advisors on their investment into the Euros80 Million Series A Financing of Antag Therapeutics. Other investors in the round included Novo Holdings, Longview Ventures (an affiliate of Broadview Ventures), and Export a . . .